COMP <GO>
GENB vs ZYME // EV/EBITDA & P/E VALUATION
Generate Biomedicines Inc. (NASDAQ) VS. Zymeworks Inc. (NASDAQ) • 15-METRIC TALLY: GENB 1
— ZYME 1
■ METRIC PARITY
LAST: $15.77 (+2.54%) • MKT CAP: $2.02B
valuation
—
LAST: $28.71 (-0.66%) • MKT CAP: $2.02B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GENB VS. ZYME)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GENB | ZYME | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -32.20% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -1.71% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 38.90% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 11.85 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 4/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.8 | 60.4 | -7.60 | ZYME | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.02B | $2.02B | $769.6K | GENB | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GENB REV | ZYME REV | GENB GROSS % | ZYME GROSS % | GENB FCF | ZYME FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $106.0M | — | — | — | -$34.5M |
| FY 2024 | — | $76.3M | — | — | — | -$112.0M |
| FY 2023 | — | $76.0M | — | — | — | -$118.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GENB // BETA —
ZYME // BETA —